Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) has entered into a Merger and Contribution and Share Exchange Agreement with KE Sdn. Bhd., which was approved by Titan’s board of directors. This reverse merger transaction will result in Titan being combined with KE. Titan will merge with TTNP Merger Sub, Inc., a subsidiary of BSKE Ltd., and become a wholly owned subsidiary of BSKE. KE shareholders may elect to exchange their shares for BSKE shares. Dato Seow Gim Shen, CEO of Titan, holds 47.4% of KE shares and, post-merger, expects to own 48.9% of the new combined company. This merger aims to drive value creation for Titan’s shareholders, although its completion is subject to several conditions, including shareholder and regulatory approvals and satisfaction of customary conditions. Detailed information about the merger can be found in Titan’s upcoming filings with the SEC.
Biotechnology, Human Capital Management (HCM) Solutions,United States, Malaysia
https://www.globenewswire.com/news-release/2024/08/19/2932437/0/en/Titan-Pharmaceuticals-Enters-Into-Merger-Agreement-With-KE-Sdn-Bhd.html